Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases, aiming to improve the lives of patients and their families. The company's lead product candidate is designed to target the underlying causes of motor neuron disease and potentially other neurodegenerative conditions.

Justin Klee

Joshua Cohen

Amylyx Pharmaceuticals

Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by systemic amyloidosis. 

Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.

Directorate General operational for Economy, Employment and Research

6K Venture Capital

Smedvig

Ifoghas Investments

Sambrinvest

Merieux Developpement

Meusinvest (Noshaq)

Kenneth Buckfire

Amyl Therapeutics

Metric
Company Name	Amylyx Pharmaceuticals
Symbol
MSH ID	COM:AMYLTX
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	BE
Stage
Employee Count	8
Website	amyltx.com
LinkedIn	amyl-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:AMYLTX

Amylyx Pharmaceuticals

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue